AU3111700A - Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity - Google Patents
Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activityInfo
- Publication number
- AU3111700A AU3111700A AU31117/00A AU3111700A AU3111700A AU 3111700 A AU3111700 A AU 3111700A AU 31117/00 A AU31117/00 A AU 31117/00A AU 3111700 A AU3111700 A AU 3111700A AU 3111700 A AU3111700 A AU 3111700A
- Authority
- AU
- Australia
- Prior art keywords
- inhibitorsof
- compositions
- methods
- inflammatory diseases
- necrosis factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20610898A | 1998-12-04 | 1998-12-04 | |
| US09206108 | 1998-12-04 | ||
| US31641599A | 1999-05-21 | 1999-05-21 | |
| US09316415 | 1999-05-21 | ||
| PCT/US1999/028856 WO2000032598A1 (en) | 1998-12-04 | 1999-12-06 | Methods and compositions for treating inflammatory diseases utilizing inhibitors of tumor necrosis factor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU3111700A true AU3111700A (en) | 2000-06-19 |
Family
ID=26901044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU31117/00A Abandoned AU3111700A (en) | 1998-12-04 | 1999-12-06 | Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU3111700A (en) |
| WO (1) | WO2000032598A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI279401B (en) | 1999-08-31 | 2007-04-21 | Incyte San Diego Inc | Heterocyclic derivatives for the treatment of diabetes and other diseases |
| AU7961800A (en) * | 1999-10-28 | 2001-05-08 | Kyowa Hakko Kogyo Co. Ltd. | Thiazolidinedione derivatives |
| JP2004511554A (en) * | 2000-10-18 | 2004-04-15 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Substituted imidazoles useful in treating inflammatory diseases |
| EA200300982A1 (en) | 2001-03-07 | 2004-12-30 | Инсайт Сан Диего, Инк. | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES |
| CA2473156A1 (en) | 2001-03-08 | 2002-09-19 | Incyte San Diego, Inc. | Rxr activating molecules |
| AU2002352706A1 (en) | 2001-11-15 | 2003-06-10 | Maxia Pharmaceuticals, Inc. | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
| US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| GB2387172A (en) * | 2002-03-28 | 2003-10-08 | Pantherix Ltd | [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
| AU2003229459A1 (en) * | 2002-05-17 | 2003-12-02 | Qlt Inc. | Methods of using thiazolidinedithione derivatives |
| FR2845000B1 (en) * | 2002-09-27 | 2005-05-27 | Oreal | USE OF A HETEROCYCLIC COMPOUND OR ONE OF ITS SALTS FOR STIMULATING OR INDUCING THE GROWTH OF HAIR AND / OR BRAKING THEIR FALL |
| EP1597255A1 (en) * | 2002-11-13 | 2005-11-23 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives and pharmaceutical compositions containing them |
| FR2858324A1 (en) * | 2003-07-30 | 2005-02-04 | Centre Nat Rech Scient | Composition used for treating microbial infections, effective particularly against rifampicin-resistant bacteria, contain new or known 5-(heterocyclylmethylene)-thiazolidine derivatives |
| JPWO2005026127A1 (en) * | 2003-09-11 | 2006-11-16 | 株式会社医薬分子設計研究所 | Plasminogen activator inhibitor-1 inhibitor |
| FI20041129A0 (en) * | 2004-08-30 | 2004-08-30 | Ctt Cancer Targeting Tech Oy | Thioxothiazolidinone compounds for use as drugs |
| KR101118842B1 (en) * | 2005-03-24 | 2012-03-16 | 한국화학연구원 | 5-1,3-diaryl-1H-pyrazol-4-ylmethylene-thiazolidine-2,4-dione derivatives useful as antitumor agent |
| KR101118768B1 (en) * | 2005-03-24 | 2012-03-20 | 한국화학연구원 | 5-3-Aryl-1-pyridyl-1H-pyrazol-4-ylmethylene-thiazolidine-2,4-dione derivatives useful as antitumor agent |
| KR101118827B1 (en) * | 2005-08-17 | 2012-03-20 | 한국화학연구원 | 5-3-Aryl-1-phenyl-1H-pyrazol-4-ylmethylene-3-alkylcarboxy- rhodanine derivatives useful as antitumor agents |
| CA2657114A1 (en) * | 2006-07-20 | 2008-01-24 | Otsuka Pharmaceutical Co., Ltd. | Nf-.kappa.b inhibitor |
| KR101159000B1 (en) * | 2010-06-18 | 2012-06-21 | (주) 에빅스젠 | Novel rhodanine derivative, process for preparing the same and pharmaceutical composition for preventing or treating AIDS comprising the same |
| US9255088B2 (en) | 2010-08-11 | 2016-02-09 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
| WO2013142346A1 (en) | 2012-03-23 | 2013-09-26 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
| WO2015070122A1 (en) * | 2013-11-08 | 2015-05-14 | The Cleveland Clinic Foundation | Protein disulfide isomerase inhibiting anticancer agents |
| CN106588909B (en) * | 2017-01-06 | 2019-08-27 | 广东工业大学 | A kind of preparation of quinoline derivatives and its application in anti-inflammatory |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998053790A2 (en) * | 1997-05-30 | 1998-12-03 | Texas Biotechnology Corporation | Compounds that inhibit the binding of vascular endothelial growth factor to its receptors |
-
1999
- 1999-12-06 AU AU31117/00A patent/AU3111700A/en not_active Abandoned
- 1999-12-06 WO PCT/US1999/028856 patent/WO2000032598A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000032598A1 (en) | 2000-06-08 |
| WO2000032598A9 (en) | 2000-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU3111700A (en) | Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity | |
| AU2212299A (en) | Compositions and methods for the treatment of tumor | |
| AU2003200731A1 (en) | Compositions and methods for the treatment of tumor | |
| AU2003200722A1 (en) | Compositions and methods for the treatment of tumor | |
| AU2003200740A1 (en) | Compositions and methods for the treatment of tumor | |
| AU2495200A (en) | Compositions and methods for the treatment of tumor | |
| GR3036364T3 (en) | Compositions and methods for treating or preventing inflammatory diseases | |
| AU1296099A (en) | Methods and compositions for treating dermatoses | |
| AU3998400A (en) | Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor | |
| AU2085201A (en) | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death | |
| IL132758A0 (en) | Methods for treating inflammation and inflammatory diseases using padprt | |
| AU2327599A (en) | Compositions and methods for treating autoimmune diseases | |
| KR100510795B1 (en) | Compositions and Methods for the Treatment of Tumor | |
| IL136110A0 (en) | Methods and compositions for the treatment of psoriasis | |
| AU9016898A (en) | Methods and compositions for treatment of restenosis | |
| AU7360000A (en) | Methods and compositions for preventing and treating prostate disorders | |
| AU1359801A (en) | Methods and compositions for treating reward deficiency syndrome | |
| AU2002235692A1 (en) | Methods and compositions for preventing and treating neutrophil-mediated diseases | |
| AU4033900A (en) | Compositions and methods for treating cell proliferation disorders | |
| AU2821295A (en) | Compositions and methods for the treatment of tumors | |
| IL124650A0 (en) | Methods and therapeutic compositions for treating cancer | |
| IL141426A0 (en) | Compositions and methods for the treatment of tumor | |
| AU5333298A (en) | Compositions and methods for tumour therapy | |
| IL143212A0 (en) | Compositions and methods for the treatment of tumor | |
| AU4515001A (en) | Compositions and methods for locally treating inflammatory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |